Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A proliferation switch for genetically modified cells

C A Blau1, K R Peterson, J G Drachman

  • 1Division of Hematology, University of Washington, Seattle 98195, USA.

Proceedings of the National Academy of Sciences of the United States of America
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protein disulphide isomerase (PDI) is protective against amyotrophic lateral sclerosis (ALS)-related mutant Fused in Sarcoma (FUS) in in vitro models.

Scientific reports·2021
Same author

The expression of HMGB1 on microparticles from Jurkat and HL-60 cells undergoing apoptosis in vitro.

Scandinavian journal of immunology·2014
Same author

The use of mitochondrial mutants in hybridization of industrial yeasts : III. Restoration of mitochondrial funktion in petites of industrial yeast strains by fusion with respiratory-competent protoplasts of other yeast species.

Current genetics·2013
Same author

Non-Utilization of sucrose by the petite mutant of a distiller's yeast.

Current genetics·2013
Same author

Use of mitochondrial mutants in the isolation of hybrids involving industrial yeast strains : IV. Characterization of an intergeneric hybrid, Saccharomyces diastaticus x Hansenula capsulata, obtained by protoplast fusion.

Current genetics·2013
Same author

The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers.

Clinical pharmacology and therapeutics·2012

Researchers developed a novel system for reversible intracellular protein dimerization using FK1012, a drug-induced dimerization mediator. This method successfully stimulated cell proliferation, mimicking erythropoietin signaling pathways.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Biotechnology

Background:

  • Receptor dimerization is crucial for cytokine signaling, such as with erythropoietin.
  • Existing methods for controlling intracellular events are limited in reversibility and specificity.

Purpose of the Study:

  • To develop a system for reversible, drug-induced intracellular protein dimerization.
  • To investigate the potential of this system in controlling cell proliferation.

Main Methods:

  • Engineered a fusion protein with the erythropoietin receptor's intracellular domain.
  • Utilized FK1012, a dimeric FK506 analog, to induce dimerization of the fusion protein.
  • Assessed cell proliferation and downstream signaling pathways (JAK2, STAT5 phosphorylation).

Related Experiment Videos

Main Results:

  • FK1012 induced dimerization of the erythropoietin receptor fusion protein.
  • This dimerization promoted proliferation of cells lacking interleukin 3.
  • FK506 competitively inhibited FK1012's effect, demonstrating reversibility.
  • Activated signaling pathways mimicked erythropoietin, with JAK2 and STAT5 phosphorylation.

Conclusions:

  • FK1012-mediated dimerization offers a precise and reversible method for stimulating cellular processes.
  • This approach holds promise for controlling genetically modified cell populations in vitro and in vivo.
  • The system effectively mimics endogenous cytokine receptor signaling pathways.